Assessment of the Effectiveness of Menopur in Intrauterine Insemination

The purpose of this study is to assess the effectiveness of Menopur to achieve clinical pregnancy in females undergoing intrauterine insemination in clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Investigational site, Elche, Alicante, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Infertile couples for over one year (primary or secondary) or infertile women (or not) with indication of PAI or DAI
Seminal sample suitable for artificial insemination treatment according to the criterion of each centre
Patient prescribed therapy with Menopur in artificial insemination

Exclusion criteria

Contraindications to intrauterine insemination
Contraindications to Menopur

Treatment and study plan

hMG

Drug

Patients with a condition

Primary outcomes

Clinical pregnancy rate

Time frame: 30 days

Secondary outcomes

Live birth rate

Time frame: 40 weeks

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Collaborators

Ferring SAU

Registry information

Official study title

Assessment of the Clinical Efficacy of Menopur® in Intrauterine Artificial Insemination (From Partner or From Donor)

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2006
First posted: May 17, 2011
Registry last updated: Mar 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed